A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma

• Patients participated voluntarily and signed informed consent；
• PTCL confirmed by histopathology；
• There must be at least one evaluable or measurable lesion that meets Lugano2014 criteria；
• The ECOG score is 0 to 1；
• ANC≥1.5×10*9/L，PLT≥75 × 10*9/L；HB≥80 g/L；TBIL≤1.5ULN；ALT or AST≤2.5 ULN； Scr≤1.5ULN；
• Use contraception during treatment and for one year after the end of treatment.

Exclusion Criteria:

• Patients with central nervous system (CNS) involvement and/or hemophagocytic syndrome；
• The estimated survival time is less than 6 months；
• History of allergy to anthracyclines or liposomes; Previous recipients of mitoxantrone or mitoxantrone liposome;Previous treatment with doxorubicin or other anthracyclines had a cumulative dose of doxorubicin > 360 mg/m2（For other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin, and the maximum cumulative dose of liposomal doxorubicin is 2460mg/m2）；
• The use of Chidamide is contraindicated;
• Impaired heart function or significant heart disease;
• Hepatitis B, hepatitis C active stage infection;
• Had undergone major surgery within 4 to 6 weeks prior or expected to undergo major surgery during the study;
• severe infection;
• Poorly controlled high blood pressure or diabetes;
• A history of active visceral bleeding within the previous 3 months
• A history of malignancy within five years;
• History of mental illness;
• A history of substance abuse or dependence;
• pregnant or lactating woman;
• The investigators did not consider it appropriate to participate in this study.